Mergers

Qiagen Thermo Fisher Bids: 2020's €43 vs EQT's €46.50

Thermo Fisher's 2020 bid for Qiagen, raised from €39 to €43, lapsed with 47.02% tendered against a 66.67% minimum. EQT's 2026 offer is 8.1% higher at €46.50, needs only 50% plus one, and builds the back-end vote into the offer.

Qiagen Thermo Fisher Bids: 2020's €43 vs EQT's €46.50

Thermo Fisher bid €39 a share for Qiagen in March 2020, raised the offer to €43 that July, and still failed when only 47.02% of shares were tendered against a lowered 66.67% minimum. EQT's agreed 2026 offer is €46.50 in cash, 8.1% above Thermo's final price, and needs only 50% of the shares plus one. Thermo Fisher ($TMO) does not appear in the documented 2026 process. The reports that named suitors this year listed buyout firms, and Qiagen has said only that it talked to "strategic and financial parties." Below is how the two bids compare on price, threshold and structure, and where that leaves $QGEN holders.

Qiagen and Thermo Fisher: the 2020 bid in brief

The 2020 deal is the obvious comparison because it failed even though it had what deals usually need: a signed agreement, board support and a cash price. Our full account of Thermo's failed 2020 Qiagen bid covers the holdout campaign and the pandemic backdrop. The short version comes from Thermo's own filings. Its July 16, 2020 Form 8-K raised the price from €39.00 to €43.00 and cut the minimum acceptance from 75% to 66.67%. Its August 13, 2020 announcement reported that 107,546,187 shares, or 47.02%, had been tendered by the August 10 deadline, so the offer lapsed.

DateEventPrice per shareMinimum acceptance
Mar 3, 2020Thermo Fisher and Qiagen sign agreement€39.0075%
Jul 16, 2020Amendment: price raised, threshold cut€43.0066.67%
Aug 10, 2020Acceptance period ends, 47.02% tendered€43.0066.67%
Aug 13, 2020Offer lapses; Qiagen owes Thermo a $95 million expense reimbursementn/an/a
Oct 21, 2026Qiagen signs with EQT-controlled Crown NL Bidco€46.5050% + 1 share

The 47.02% result left Thermo 19.65 percentage points short of its lowered bar (arithmetic: 66.67 − 47.02).

Price: €46.50 against €39 and €43

EQT is offering 19.2% more than Thermo's opening bid (arithmetic: 46.50 ÷ 39.00 − 1) and 8.1% more than its final €43 (arithmetic: 46.50 ÷ 43.00 − 1). Thermo's bump from €39 to €43 was 10.3% (arithmetic: 43 ÷ 39 − 1), and it was not enough.

The premiums are measured differently in each deal, so they are not directly comparable. The 2026 announcement prices EQT's offer 40.3% above Qiagen's €33.15 XETRA close on July 8, 2026, the last day before reports of buyout interest. Thermo's premium was measured against Qiagen's share price in March 2020. The plainer comparison is in euros: holders who refused €43 in 2020 are now being offered €3.50 more, six years later.

In dollars, the €46.50 offer was worth about $52.18 at the November 10, 2026 EUR/USD rate of 1.1222. $QGEN closed at $50.51 that day. Our main page on the EQT offer covers that spread and what it prices in.

How the 2026 structure differs

A back-end squeeze is not new. Thermo's 2020 offer document, filed with the SEC, also described post-offer measures, including an "Asset Sale and Liquidation" route. The difference this time is how hard it is to reach that stage.

  • Lower bar: in 2020, holders of just over a third of the shares could sink the deal by not tendering, even after the threshold was cut to 66.67%. In 2026 the bar is 50% plus one share, so blocking takes half the shares.
  • The vote happens inside the offer: the EGM on the Post-Closing Measures takes place during the initial acceptance period, and the boards must take their Implementation Decision before the period ends. That way the back-end is settled before anyone is paid.
  • A rule aimed at holdouts: under the Business Combination Agreement, the boards will proceed if 80% of votes cast approve the measures. Below 80%, they may still proceed with the support of "a substantial majority". In judging that, they can discount holders who bought after the announcement "with the aim of frustrating the transaction or pursuing event-driven hedge fund strategies."
  • Different buyer, different risk: Thermo was a strategic buyer in the same industry. EQT is a financial buyer, backed by €5,966.9 million of committed equity and with no financing condition. Its regulatory list covers competition, foreign-investment screening and CFIUS, with a €300 million reverse fee if those approvals fail.

The lower bar is not a guarantee. The 47.02% Thermo collected would still fall about 3 points short of 50% (arithmetic: 50 − 47.02 = 2.98). Holders who do not tender and are left at the back-end get the offer price less withholding taxes, which the companies say may net less than tendering. This is general information, not tax or legal advice. Our Qiagen takeover timeline covers each step.

Was Thermo Fisher among the 2026 bidders?

Nothing on the record says it was. When it confirmed the August 10, 2020 deadline, Thermo stated in its August 4, 2020 release that it "will not launch another offer in the event the current offer fails to meet the minimum acceptance threshold."

In 2026, Bloomberg reported on July 9 that EQT and Advent had shown early interest and that KKR had also expressed interest. It added that strategic players could also be drawn in, without naming any. After the deal, Börsen-Zeitung reported that KKR, Advent, Bain and TPG had also been interested, and it mentioned Thermo Fisher only in connection with the 2020 bid. Qiagen's chairman said the boards considered "discussions with strategic and financial parties" but did not name them. Our pre-deal roundup of the Qiagen takeover talks lists every report. On that record, Thermo's 2026 role, if any, has not been disclosed. For more deal coverage, see the Markets section or the homepage.

Bull/Bear Verdict

Bull Case: EQT pays 8.1% more than Thermo's failed €43, needs only 50% plus one instead of 66.67%, and the boards can proceed with the back-end even below an 80% EGM vote while discounting event-driven holdouts.

Bear Case: In 2020 a cut threshold and a price bump still fell short, and 47.02% would miss even today's 50% bar. A financial buyer also brings its own regulatory and CFIUS review, and the 2026 deal runs to a mid-2027 expected close.

FAQ

How much did Thermo Fisher offer for Qiagen?

€39 a share in cash when the deal was signed on March 3, 2020, raised to €43 on July 16, 2020. The offer lapsed on August 13, 2020 after only 47.02% of shares were tendered.

Is Thermo Fisher bidding for Qiagen in 2026?

There is no public record of a 2026 Thermo Fisher bid. Qiagen signed with EQT on October 21, 2026, and the reports that named 2026 suitors listed buyout firms. In 2020, Thermo said it would not launch another offer if that one failed.

Is EQT's offer higher than Thermo Fisher's?

Yes. €46.50 is 8.1% above Thermo's final €43 and 19.2% above its opening €39.

Why is the 2026 acceptance threshold lower?

The EQT agreement sets the bar at 50% of outstanding capital plus one share and settles the back-end through an EGM vote during the offer. In 2020 the bar was 75%, later cut to 66.67%.

Share X LinkedIn Email
Disclaimer: The information provided is for informational purposes only and is not intended as financial, legal, or tax advice. Trading around earnings involves significant risk and increased volatility. Past performance is not indicative of future results. No strategy can guarantee profits or protect against loss. Consult a professional advisor before acting on any information provided.

More in Mergers · Full archive